Showing results (11-20 of 237) with videos related to

Sort By:
Pageof 24
Cancers|February 11, 2023
Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter StudyKai Kröger, Jan Siats, Andrea Kerkhoff, et al.
Blood Advances|January 10, 2024
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine modelKarin Frebel, Jörn C Albring, Anika Wohlgemuth, et al.
European Journal of Medical Research|March 16, 2023
Impact of intensified contact precautions while treating hematopoietic stem cell transplantation recipients during aplasiaChristian Böing, Christian Reicherts, Neele Froböse, et al.
Cancers|July 2, 2021
Pulmonary Toxicity after Total Body Irradiation-An Underrated Complication? Estimation of Risk via Normal Tissue Complication Probability Calculations and Correlation with Clinical DataMichael Oertel, Christopher Kittel, Jonas Martel, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2022
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE TrialMatthias Stelljes, Anjali S Advani, Daniel J DeAngelo, et al.
European Urology|June 14, 2008
Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinomaChristian Doehn, Norbert Esser, Hans-Gerd Pauels, et al.
Annals of Hematology|December 20, 2020
Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemiaLinus Angenendt, Isabel Hilgefort, Jan-Henrik Mikesch, et al.
Expert Review of Hematology|January 8, 2025
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature reviewDavid I Marks, Ryan D Cassaday, Josep-Maria Ribera, et al.
Advances in Therapy|May 30, 2019
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic LeukemiaIrina Proskorovsky, Yun Su, Kyle Fahrbach, et al.
Cancers|November 27, 2021
The Burden of Survivorship on Hematological Patients-Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell TransplantationMichael Oertel, Jonas Martel, Jan-Henrik Mikesch, et al.
Pageof 24